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INTRODUCTION 
The peroneal muscular atrophy was 
described about 120 years ago by Charcot, 
Marie and Tooth in Paris and England, 
respectively. The described disorder was a 
familial and neurological disease. It was 
called CMT, to respect Charcot, Marie and 
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ABSTRACT 
Background and aims: Charcot Marie Tooth disease (CMT) is the most prevalent 
hereditary neuropathy and its frequency is 1 in 2500. CMT is a heterogeneous disease 
and has different clinical symptoms. The prevalence of CMT and involved genes differ in 
different countries. CMT patients experience considerable sleep problems and a higher 
risk of decreased quality of life. In this work it was aimed to provide a review on the 
genetic and epidemiologic aspects of this disease. 
Methods: In the current review article, we performed a literature search on the 
epidemiology of Charcot–Marie–Tooth disease” and provided a brief review on 
epidemiology, genetic, and complications of CMT. Databases Web of Science and 
PubMed were searched using the Endnote software for the publications on CMT during 
2000 to 2016. 
Results: Charcot Marie Tooth disease has different prevalence around the world and is 
the most common neuropathy. Epidemiological studies have estimated the prevalence of 
CMT in Japan 1/9200, in Iceland 1/8300, in Spain 1/3500 and in Italy 1/5700.The 
patients have different phenotype and the age of onset. There is a variety of inherited 
patterns of disease and many genes have been identified responsible whose mutations are 
main cause of the disease. 
Conclusion: Due to the impact of this kind of disabilities on the national health, further 
studies seem to be necessary to gain better knowledge of the disease particularly in the 
regions with higher prevalence. Moreover molecular biology services offered by genetic 
laboratories can reduce the incidence of disorder. 
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Tooth who described it for the first time. 
Charcot Marie Tooth disease (CMT) is the 
most prevalent hereditary neuropathy and its 
frequency is 1 in 2500. The other name of 
CMT disease is hereditary motor and 
sensory neuropathy(HMSN).
1,2
 Because of 
involving more than 80 genes in CMT, it is a 
heterogeneous group of inherited peripheral 
neuropathies.
3,4
 Based on electrophysiological 
index, CMT is subdivided into two major 
forms: demyelinating and axonal. In the 
demyelinating type, motor nerve conduction 
velocity (MNCV) is under 38 m/s whereas in 
axonal forms, MNCV is normal (above  
38 m/s), but axons are affected. In the 
intermediate type of this disorder, intermediate 
MNCV about 25-45 m/s and/or heterogeneous 
clinical manifestation is common.
5
 The CMT 
disease has different inheritance pattern 
(including Autosomal Recessive(AR), 
Autosomal Dominant(AD), X-linked, and 
mitochondrial). In addition, the onset of CMT 
can be in different ages and clinical features 
varies in patients.
6
 Despite a high number of 
publications providing comprehensive and 
detailed information on CMT, there is little 
about the epidemiology of this disease. In this 
work, it was aimed to provide a concise 
review on the genetic and epidemiologic 
aspects of this disease. Databases Web of 
Science and PubMed were searched using the 
Endnote software for the publications on CMT 
during 2000 to 2016. 
From the genetic perspective, Charcot 
Marie Tooth is a heterogeneous disease, but 
the clinical phenotype and manifestation is 
homogeneous and similar. This similar 
phenotype includes the weakness of distal 
limb muscles) especially the peroneal 
compartment of leg), loss of sensation in the 
distal extremities, skeletal abnormalities and 
reduction or lack of reflexes in deep tendons.
7
 
Triad flaccid paresis, atrophy, and decreased 
or loss of reflexes are outcomes of the lower 
motor neuron damage. The severity of the 
disease ranges over a wide spectrum. Age of 
onset is different among the patients, ranging 
from a floppy infant to an elderly man with 
slowly progressive peripheral neuropathy.
8
 
The classic clinical picture of  Charcot Marie 
Tooth disease is pescavus, hammertoes, 
atrophy in muscles, weakness in the distal 
compartment of the legs, lack of vibratory 
sensation, absent of touch sensation and loss  
of reflexes in Achilles tendon.
9,10
 
The identification of inheritance pattern is 
the first step of CMT classification. CMT is 
inherited via autosomal dominant, autosomal 
recessive and X-linked patterns. The second 
step of classification is according to the 
process of neuropathy disorder in each 
subset.
10,11
 According to electrophysiological 
standards CMT is usually divided into two 
classes; demyelinating and axonal forms 
(CMT1 and CMT2 respectively). In CMT 
type 1 motor nerve conduction velocities 
(MNCV) is less than 38 m/s and the effect of 
demyelination and remyelination in nerves can 
be seen in sural nerve biopsy. In CMT type 2 
motor nerve conduction velocities is 
somewhat decrease or even normal
12
. CMT4 
is Autosomal recessive and CMTX is not 
dependent to the Nerve Conduction Velocity. 
To determine the subtypes in CMT 
disease, the mutant gene should be 
distinguished. It is known that more than 40 
genes can cause CMT.
13
 Among CMT 
subtypes, duplication in PMP22 geneis cause 
of the most common form of the disease, 
CMT1A. This subtype contains 70-80% of the 
CMT1 (demyelinating)cases.
14
 The subtype 
CMT2 manifested by MPZ mutations is 
involved in 10–30% of the CMT cases.15 
Furthermore, GJB1 and GDAP1 mutations 
lead to CMTX1 and CMT4A respectively. 
The clinical features are sometimes 
uncommon for CMT type 2, CMT type 4, 
and CMTX. For instance, CMT4 is recessive 
with early onset and severe symptoms.
14
 The 
cause of demyelinating form of CMT with 
Autosomal Dominant inheritance pattern 
(CMT type 1A) is usually PMP22  
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gene-duplication (on 17p11.2 locus) and it is 
almost 20% of all CMT cases with 
neuromuscular problems and a chronic 
peripheral neuropathy. Other causes for 
CMT1 (demyelinating) include mutations in 
P0 (1q22), LITAF (16p13) and EGR2 
(10q21) genes.
16
 Table 1 and Table 2 
summarize the main types of CMT together 
with the responsible gene and their 
chromosomal locus. 
 
Table 1: The most common subtypes of 
CMT disease and the involved genes 
CMT subtype Mutation 
CMT1A PMP22 duplication 
CMT2A2 MFN2 
CMTX1 GJB1 
CMT4A GDAP1 
 
Table 2: The chromosomal locus for the 
most prevalent types of CMT1 
The mutant gene Locus 
PMP22 17p11.2 
P0 1q22 
LITAF 16p13 
EGR2 10q21 
 
Charcot Marie Tooth is a chronic 
disease and has an unpleasant effect on 
condition of patient’s life. The undesirable 
effect impact different part of life, including 
mental and physical aspects.
9
 
In CMT, disturbed sleep and respiratory 
system dysfunction may also be seen, which 
include the following items: obstructive 
apnea in sleep, streaked legs syndrome, vocal 
cord disorder, laryngeal neuron dysfunction 
and respiratory system impairment.
17
 
In Germany, a large study was 
conducted on 200 patients with Charcot 
Marie Tooth
13
 wherein, patients complained 
about fatigue, lack of good sleep and feeling 
sleepy during the day hours. Other 
symptoms including dysphagia, dyspnea and 
obstructive apnea in sleep was described in 
another report.
18
 
Due to the lack of specific 
recommendations for the respiratory and 
sleep disorders, individuals need long-term 
care. Moreover, there are limitations for 
treatment of CMT patients during illness. 
Some reports show that during the 
pregnancy, patient’s signs and symptoms 
become worse.
19
 In case of surgery, regional 
anesthesia is a good alternative to 
anesthesize rather than general anesthesia 
during pregnancy.
19
 
CMT has been shown to increase the risk 
for complications during delivery, 
specifically abnormal birth presentation, 
post-partum bleed, and with higher rates of 
emergency interventions during delivery.
20
 
Many medications can cause patient's 
condition worse. For example, progesterone 
antagonists that are prescribed for treatment 
of CMT patients lead to abnormal baby born, 
dystocia and bleeding. Additionally, 
chemotherapy drugs like vinca alkaloids and 
taxol that target cell microtubules causing 
them depolymerized, lead to worsening 
CMT.
21
 It seems that these drugs cause 
disruption of axonal transportation and thus 
worsen or accelerate the development of new 
neuropathy. Chemotherapy drugs are not the 
only risk factors for the Charcot Marie Tooth 
disease, there is a large list of interventional 
medications prepared by the CMT 
Association which is regularly updated.
22
 
In all epidemiological studies, the 
important issue is whether the results can be 
generalize or not, and this depends on the 
population chosen for the study. In clinical 
trials, there is a non-partisan data collection, 
because the members elected in a clinical 
population and large families and patients 
with severe disabilities also participated in 
the study.
23
 However, sporadic cases are 
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important because it shows disease with 
autosomal recessive inheritance pattern or a 
de-novo mutation. There are some items  
that can increase or decrease the estimation 
of disease prevalence. For example, 
misclassification of sporadic and familial 
non-CMT cases can increase the estimation 
and the CMT patients who do not participate 
in the study can reduce the estimation  
(eg, CMT2 has late onset and the person is a 
carrier of the disease but does not participate 
in the study).
24
 Epidemiological studies have 
estimated the prevalence of CMT in 
Japan1/9200, in Iceland1/8300, in Spain 
1/3500 and in Italy 1/5700.The difference in 
rates is mainly due to different methods used 
to determine and diagnose disease and 
sometimes because of human ethnicity and 
unequal distribution of point mutations in 
the world and dominance of founder effect 
in some areas. Clinical studies conducted 
that CMT1 outbreak is more than CMT2 and 
only one exception is in Japan, which 
founder effect occurred for MPZ gene 
(Thr124Met).
25
 In a study conducted by G. 
J. Braathen1 in Akershus (the East Norway 
County), it was estimated that 13.6% of the 
families carry the PMP22 gene duplication 
while CX32 mutation was estimated to be 
about 6.2%. Moreover, MFN2 mutation and 
MPZ mutation were estimated around 6.2% 
and 4.8%, respectively.
26
 The prevalence of 
duplication/deletion of PMP22 and MFN2 
point mutation in the general population was 
less than clinical population, while for point 
mutation in CX32 the similar prevalence in 
both populations was estimated.
14,27-29 
 
DISCUSSION 
CMT is a heterogeneous disease and 
has different pattern of inheritance, different 
age of onset and different clinical 
symptoms. The outbreak and involved genes 
vary in different countries. Identifying 
common mutations in each region in the 
world can help to identify the involved 
proteins and it is good for correct diagnosis 
of the disease and may be entered in the 
world of treatment. Unfortunately, 
epidemiological studies on CMT have not 
been yet conducted in Iran. Hopefully, the 
researches currently conducted by our group 
could identify affected individuals and 
families. This information together with our 
molecular genetic testing will further be of 
benefit to the patients and their families and 
will prevent from affected child birth. 
 
CONCLUSION 
Due to the impact of this kind of 
disabilities on the national health, further 
studies seem to be necessary to gain better 
knowledge of the disease particularly in the 
regions with higher prevalence. Moreover 
molecular biology services offered by 
genetic laboratories can reduce the incidence 
of disorder. 
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